Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Study Reports Real-World Pembrolizumab Toxicity in TNBC
TOPLINE: In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received pembrolizumab developed immune-related adverse events — findings that are comparable, overall, to those from the landmark KEYNOTE-522 trial. However, there were…
English